Lycium barbarum Reduces Abdominal Fat and Improves Lipid Profile and Antioxidant Status in Patients with Metabolic Syndrome
Table 2
Sociodemographic, anthropometric, and drug use characteristics in patients with metabolic syndrome, belonging to the control group (C) and supplemented group (S).
Variables
Groups
C ()
S ()
Mean ± SE
Mean ± SE
Age (years)
49.17 ± 2.56
52.6 ± 2.24
Age group
Up to 59 years
20 (80%)
19 (76%)
60 years and over
5 (20%)
6 (24%)
Gender
Female
18 (72%)
17 (68%)
Male
7 (28%)
8 (32%)
BMI (kg/m2)
33.72 ± 1.28
32.98 ± 0.71
Adults
Eutrophy
—
—
Overweight
7 (33.3%)
5 (21.7%)
Obesity
14 (66.5%)
16 (73.8%)
Elderly
Eutrophy
—
—
Overweight
2 (50%)
2 (66.6%)
Obesity
2 (50%)
1 (33.3%)
Systolic blood pressure (mmHg)
128 ± 6
131.6 ± 3
Diastolic blood pressure (mmHg)
82 ± 3
84.8 ± 2
Drugs in use
ACEI/ARBs
20 (80%)
21 (84%)
Statins
13 (52%)
12 (48%)
Oral hypoglyclers
9 (36%)
7 (28%)
Diuretics
8 (32%)
7 (28%)
Outcome presented in the form of n (%). SE: standard error; ACEI: angiotensin-converting enzyme inhibitor; ARBs: angiotensin receptor blockers II.
